Atnahs Pharma Denmark ApS: Financial statements 2023
CVR: 36699051
Source: annual report 2023, Danish Business Authority
01/04/2022 – 31/03/2023
Atnahs Pharma Denmark ApS (CVR 36699051) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 517,225,669 and a net result of DKK 14,720,135 compared with DKK 3,647,068 the year before. The profit margin was 2.8%. Equity in the 2023 report amounted to DKK 14,862,414. The solvency ratio was 3.6%.
- Revenue
- DKK 517,225,669
- Gross Profit
- DKK -19,380,038
- Profit/Loss
- DKK 14,720,135
- Equity
- DKK 14,862,414
- Total Assets
- DKK 407,346,224
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 517.2M | -19.4M | 14.7M | 14.9M | - |
| 2022 | - | 9.8M | 3.6M | 142K | - |
| 2021 | - | 5.1M | 275K | -3.5M | - |
| 2020 | - | -1.3M | -1.4M | -3.8M | - |
| 2019 | - | 779K | -1.1M | -2.4M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 6, 2023, Jesper Wilhelm Voss has left the board of directors of Atnahs Pharma Denmark ApS.
As of October 6, 2023, James Sang Bum Lee is registered as director of Atnahs Pharma Denmark ApS.
As of October 6, 2023, Amit Vijaykumar Patel has stepped down as director of Atnahs Pharma Denmark ApS.
As of May 24, 2023, James Sang Bum Lee has joined the board of directors of Atnahs Pharma Denmark ApS.
As of May 24, 2023, Felipe Andres Florez Arango has left the board of directors of Atnahs Pharma Denmark ApS.
About Atnahs Pharma Denmark ApS
Atnahs Pharma Denmark ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Pharmamentum ApS. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported revenue of EUR 52,583,756 and a net result of EUR 12,487 compared with DKK 47,843 the year before. Equity in the 2026 report amounted to EUR 2,094,136.